Clovis Oncology Inc (NASDAQ: CLVS) is a commercial stage biotechnology company engaged in developing and commercializing oncology treatments worldwide. The Company develops diagnostic tools through its partners, which can identify patients who will benefit the most from its developmental programs, focused on targeting specific subsets of cancer. The Company’s...
Celsion Corporation (NASDAQ: CLSN) announced the receipt of a Fast-Track Designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy that is currently undergoing Phase II trials for the treatment of advanced ovarian cancer. The candidate is an IL-12...
Fabry Disease also known as angiokeratoma corporis diffusum or alpha-galactosidase A deficiency, is an inherited disorder characterized by the buildup of globotriaosylceramide, a type of fat in the body’s cells and results in numerous disorders such as acroparesthesias (burning, tingling, or prickling sensation in extremities),...
The American Cancer society estimates that in 2019, there will be around 22,530 new diagnoses of Ovarian Cancer and 13,980 women will succumb to the disease. It is the fifth largest cause for death in women, with over 1 in 78 chances of acquiring this...
PhaseBio’s (NASDAQ: PHAS), PB2452 is the new drug on the block, which has received a breakthrough therapy status from the FDA in April 2019. The company’s stock rose by almost 32%, on the day it announced the news. It acts as a reversal agent for...
Gonorrhoea, caused by a bacterial pathogen N. gonorrhoea, is the second most commonly reported sexually transmitted disease in the U.S alone. The data made available by Centres for Disease Control and Prevention (CDC) shows that in 2017, a total of 555,608 cases of gonorrhoea were reported...
